Market Overview

UPDATE: Goldman Sachs Raises PT on Regeneron Pharmaceuticals Following Complete Phase 3 Eye Drug Data

Share:
Related REGN
Regeneron Bounces Higher Off Support
Biotech Bubble Valuations From Sam Islay
Bulls Hold The Line As Market Coils In Anticipation Of A Bigger Move (Seeking Alpha)

In a report published Monday, Goldman Sachs analyst Terence Flynn reiterated a Buy rating on Regeneron Pharmaceuticals (NASDAQ: REGN), and raised the price target from $329.00 to $355.00.

In the report, Goldman Sachs noted, “REGN reported complete Phase 3 data for key eye drug, Eylea for a new indication (DME, vision loss due to diabetes) at the Retina Society conference. The data were in line with our expectations and we anticipate they will support approval for a broader label and drive uptake/growth.”

Regeneron Pharmaceuticals closed on Friday at $305.65.

Latest Ratings for REGN

DateFirmActionFromTo
Mar 2015Chardan CapitalInitiates Coverage onBuy
Feb 2015BernsteinInitiates Coverage onOutperform
Feb 2015Piper JaffrayDowngradesOverweightNeutral

View More Analyst Ratings for REGN
View the Latest Analyst Ratings

Posted-In: Goldman Sachs Terence FlynnAnalyst Color Price Target Analyst Ratings

 

Related Articles (REGN)

Around the Web, We're Loving...